Levetiracetam-associated pancytopenia

Excerpt

Levetiracetam (LEV) is an anti-seizure drug (ASD) that acts by interfering with the release of the neurotransmitter stored in the vesicle by binding to the synaptic vesicle protein SV2A. While the most common adverse effects of LEV include fatigue, drowsiness, headache, dizziness, diplopia, behavioral disorders and depression, bone marrow suppression is rarely seen [1]. There are few case reports in the literature about the relationship between LEV and pancytopenia. In this report, we highlight the possibility of pancytopenia, a rare but serious adverse effect associated with LEV.Author names: Please confirm if the author names are presented accurately and in the correct sequence (Esra Kochan Kizilkilic). Also, kindly confirm the details in the metadata are correct. author names and the details in the metadata are correct.  …